S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:IMGN

ImmunoGen (IMGN) Stock Forecast, Price & News

$15.87
-0.13 (-0.81%)
(As of 09/29/2023 ET)
Compare
Today's Range
$15.76
$16.11
50-Day Range
$14.09
$19.52
52-Week Range
$3.61
$20.69
Volume
3.64 million shs
Average Volume
3.20 million shs
Market Capitalization
$3.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.88

ImmunoGen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.1% Upside
$22.88 Price Target
Short Interest
Bearish
7.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.62mentions of ImmunoGen in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$25.38 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.12) to $0.14 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

125th out of 972 stocks

Pharmaceutical Preparations Industry

34th out of 446 stocks


IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

IMGN Price History

IMGN Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
ImmunoGen (NASDAQ:IMGN) Stock Price Down 2.7% After Insider Selling
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
ImmunoGen Names Lauren White as Finance Chief
ImmunoGen Appoints Lauren White As CFO
JP Morgan Upgrades Immunogen
JP Morgan Upgrades Immunogen (IMGN)
Immunogen Inc.
10 Analysts Have This to Say About Immunogen
ImmunoGen medical chief steps down
Barclays Reaffirms Their Buy Rating on ImmunoGen (IMGN)
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Company Calendar

Last Earnings
7/31/2023
Today
9/30/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
277
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$22.88
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+44.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-222,930,000.00
Pretax Margin
-94.92%

Debt

Sales & Book Value

Annual Sales
$108.78 million
Book Value
$0.71 per share

Miscellaneous

Free Float
236,322,000
Market Cap
$3.95 billion
Optionable
Optionable
Beta
1.00

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Mark Joseph EnyedyMr. Mark Joseph Enyedy (Age 59)
    Pres, CEO & Director
    Comp: $1.28M
  • Ms. Renee Lentini (Age 45)
    VP of Fin. & Chief Accounting Officer
    Comp: $430.52k
  • Ms. Stacy A. Coen (Age 52)
    Sr. VP & Chief Bus. Officer
    Comp: $584.04k
  • Dr. Michael J. Vasconcelles M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $304.62k
  • Ms. Lauren A. White M.B.A. (Age 44)
    Sr. VP & Chief Financial Officer
  • Anabel Chan
    Head of Investor Relations
  • Mr. Daniel S. Char J.D. (Age 62)
    Sr. VP, Chief Legal Officer & Sec.
  • Ms. Courtney O'Konek
    Sr. Director of Corp. Communications & Investor Relations
  • Ms. Audrey Bergan
    Sr. VP & Chief HR Officer
  • Dr. Theresa G. Wingrove (Age 65)
    Sr. VP of Regulatory Affairs & Quality













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2023?

7 analysts have issued 1 year target prices for ImmunoGen's shares. Their IMGN share price forecasts range from $16.00 to $27.00. On average, they anticipate the company's stock price to reach $22.88 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the beginning of the year. Since then, IMGN stock has increased by 220.0% and is now trading at $15.87.
View the best growth stocks for 2023 here
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The biotechnology company earned $83.20 million during the quarter, compared to analyst estimates of $49.15 million. ImmunoGen had a negative net margin of 96.02% and a negative trailing twelve-month return on equity of 76.92%. The firm's revenue for the quarter was up 485.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2023 earnings guidance on Monday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $15.87.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.95 billion and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 277 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -